CD163 and neoplasm: Although sCD163 levels were higher in patients with p53-deficient tumours, the prognostic value of sCD163 was independent of TP53 mutations and other clinical factors such as MIPI, Ki-67 or blastoid morphology, while low sCD163 levels could identify patients with a favourable prognosis (18).